NCT07046676 Pharmacogenetics-Based Study on Individualized Use of Sodium Valproate
| NCT ID | NCT07046676 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | The First Affiliated Hospital of University of South China |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 312 participants |
| Start Date | 2022-12-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 312 participants in total. It began in 2022-12-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sodium valproate (VPA) is a first-line prescription drug widely used in the treatment of epilepsy. However, in clinical applications, it has been found that there is a large individual variation in the blood concentration of VPA. In particular, excessively high blood drug concentrations can lead to various side effects, especially hepatotoxicity. Blood drug concentration monitoring can reduce the toxic and side effects of VPA to a certain extent and improve its effectiveness, but it is too cumbersome. A large number of studies have shown that the efficacy and toxic side effects of VPA are closely related to its in vivo metabolism process. The in vivo metabolism of VPA is affected by many factors, and the genetic polymorphism of drug-metabolizing enzymes is an important factor leading to differences in blood drug concentrations and affecting the dosage of VPA. The three products generated by the biotransformation of VPA by CYP450 enzymes are all related to hepatotoxicity. The formation of 4-ene-VPA is largely catalyzed by CYP2C9 and CYP2A6. Mutations in the CYP2A6 gene may be related to VPA hepatotoxicity, but there is a lack of further direct evidence. 50% of VPA in the body is acidified and metabolized into inactive products by uridine diphosphate glucuronosyltransferase (UGT) through phase II conjugation reactions. However, there is evidence that the genetic polymorphism of UGT can significantly affect the blood drug concentration of metformin. Based on the above research, we selected CYP2A6, UGT1A6, etc. as candidate genes, and studied the impact of genetic polymorphisms on the individual differences of sodium valproate through association analysis, with the hope of establishing a genetic model for optimal dosage and providing new strategies for the individualized use of VPA.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with epilepsy (primary epilepsy, secondary epilepsy) and with complete clinical data * Regular use of valproic acid sodium for at least 5 days (with blood drug concentration reaching a steady state) and strong medication compliance * Patients using combined anti-epileptic drugs or using valproic acid sodium alone * Patients without significant liver or kidney dysfunction, and not in the pregnancy period Exclusion Criteria: * Patients with incomplete data, poor compliance, and those whose blood drug concentration was not measured at the correct concentration * Patients with major respiratory, gastrointestinal, liver, kidney or other serious diseases * Patients using valproic acid solely for epilepsy prevention * Patients who have used valproic acid for more than 5 days but have frequently changed the dosage form during the process * Patients over 65 years old and in the 1CU
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07046676 clinical trial?
This trial is open to participants of all sexes, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07046676 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07046676 currently recruiting?
Yes, NCT07046676 is actively recruiting participants. Contact the research team at zhoujiecan@fsyy.usc.edu.cn for enrollment information.
Where is the NCT07046676 trial being conducted?
This trial is being conducted at Hengyang, China.
Who is sponsoring the NCT07046676 clinical trial?
NCT07046676 is sponsored by The First Affiliated Hospital of University of South China. The trial plans to enroll 312 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.